# Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

> **NCT02227914** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Amgen**

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** Oprozomib
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02227914
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-12
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study stopped due to administrative reasons
- **Last updated:** 2017-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227914, "Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02227914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*